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Challenges for the sustainability of university-run 
biobanks  
 
 
Abstract  
  
Most university biobanks begin like other university research projects, i.e. with an idea conceived by an individual 
researcher in pursuit of his/her own research interests, publications, funding and career. Some biobanks, however, 
come to have scientific value that goes beyond the projects that were initially responsible for the collection of the 
samples and data they contain. Such value may derive from inter alia the uniqueness of the samples in terms of 
their sheer volume, the quality of the samples, the ability to link the samples with information retrieved in disease 
registries, or the fact that the samples represent very rare diseases. This paper focuses on biobanks of this kind, 
and the special obligations that publicly funded universities have to ensure the sustainability of biobanks with 
continued scientific value. We argue that universities should adopt policies to deal with the various, diverse issues 
which may arise during the lifecycle of a biobank. The policies should be flexible, accommodate the freedoms of 
individual researchers, and reflect the multifaceted nature of biobanks. Yet they should be specific enough to 
provide guidance and robust enough to safeguard legal norms and ethical values. The paper sets out concrete 
recommendations which universities should consider and act upon. 
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Introduction 
  
Universities play an important role in the production of knowledge through scientific research1, 2. In this knowledge 
production process, universities become sites where, data, as well as physical materials, are collected and stored 
over time. Traditionally, universities have sought prestige by developing their library collections3 or investing in 
the technical equipment made available to research groups. Institutional repositories have also become an 
important resource that universities develop to collect and organize the collective output of their staff.4 
Furthermore, a number of international initiatives have launched policies to encourage the systematic collection 
and archiving of data collected using public funding.5, 6 Finally, many countries have established repositories or 
archives for accumulated data. Examples include The UK Data Archive (http://www.data-archive.ac.uk/) and The 
Finnish Social Science Data Archive (http://www.fsd.uta.fi/en/). 
  
Another valuable university resource is the biobank. Biobanks play an important role in the development of 
biomedical research, and the large collections of samples of human tissue and data held in them are often described 
as a kind of Eldorado or goldmine waiting to be discovered and used for medical breakthroughs to the benefit of 
mankind.7, 8 Although there is a large variety of different types of biobank, many are located in publicly funded 
universities and are run wholly or in part by university staff, and there appears to be little consensus or standards 
on how to manage these collections in the long run. Biobanks are also becoming important nodes around which 
international research collaboration is arranged, often with countries or regions with vastly different legal and 
ethical frameworks for protecting donor rights.9 Although during the past two decades there has been a great deal 
of research on the governance of biobanks,10, 11  universities, as institutions of higher learning, have shown 
surprisingly little interest in the development of national or international standards and guidelines for their long-
term sustainability. Chalmers et al. (2016)12 have suggested that the lack of attention to the sustainability of 
biobanks may prove to be their biggest challenge yet. 
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Governance of biobanks involves structurization of the processes and relationships involved in the pursuit of the 
goals defined by biobanking institutions.13 It may also reflect the exercise of authority by state actors to steadily 
and effectively manage the development of biobanks. This management is often achieved through practices, 
principles, regulations and other guidelines. Governance may thus involve self-regulation as well as legal 
parameters.14 The growth of the biobanks which have evolved from university-based sample collections within 
most universities begins like other university research projects, i.e. with an idea conceived by an individual 
researcher or research group in pursuit of their own research interests, publications, funding and careers. Over 
time, successful biobanks take on a life of their own, however, and expand beyond the original idea and plans. 
Collections grow as new funding is secured, and as international research ties are established leading to samples 
and data being exchanged across borders. New researchers join the project, and others leave (sometimes with 
‘their’ samples in the back of the car or ‘their’ data on a memory stick). Such developments mean that serious 
consideration must be given to university-based governance of the establishment, maintenance and protection of 
biobanks. 
  
The buildup of biobanks in incremental steps without central coordination poses a number of challenges for 
universities. University administration is normally involved only if necessary, and so far most universities have 
probably been happy not to be bothered with additional tasks. For these reasons, many universities lack systematic 
and coherent policies on biobanking and find themselves “accidental biobankers”. However, universities in which 
biobank collections are maintained must accept and shoulder the practical, legal and ethical responsibilities 
associated with biobanking. Practically, the necessary infrastructure, including funding, must be provided; legally, 
rules regarding the collection and sharing of samples and data must be observed; and ethical obligations pertaining 
to research must be respected. Universities attend to all of these with a view of furthering the immediate interests 
of their employees (and thus themselves). Decisions to expand or close biobanks are made by the researchers 
involved, and within the scope of possibilities defined by their funding and research interests. 
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Universities also have an ethical responsibility to ensure that resources maintained on their premises are used to 
their full potential. Non-use or underuse of important collections, or the slow destruction of collections due to 
negligence, amounts to a waste of resources that have been collected using public funding.15, 16 
  
Some biobanks are connected with issues, values or interests which go beyond the individual and short-term 
interests of the researcher, research project or university they are associated with. We argue that where such 
biobanks are concerned universities should recognize that they have a responsibility which goes beyond those 
following from their own, immediate interests and reflects general societal interests. Unique (one-of-a-kind) 
biobanks will often fall into this category, since their destruction could gravely harm future research. A case in 
point is the Copenhagen Family Bank (CFB), which contains DNA and phenotypic/clinical data from >900 large 
families [http://www.genomedenmark.dk/english/ethics/patientmaterials/]. CFB has been used to map numerous 
genetic loci, from cystic fibrosis (CF)17, 18, 19 to blue eyes,20 and it has lately formed the basis for a Danish reference 
genome project.21 For this and similar biobanks, societal interest in preserving the data goes far beyond the short-
term interests of its present keepers. Other biobanks may merit special attention because of legislative or 
contractual restrictions which, for example, limit access, or use, and which have to be respected also by future 
generations of users of the biobank. 
 
The long-term use of samples for secondary purposes may also involve significant ethical, legal, and financial 
implications for universities. Arizona State University, for example, agreed to pay 41 members of the Havasupai 
Tribe 700 000 USD for improper use of their blood samples in genetic research.22 The samples had originally been 
collected in 1990 for a study on diabetes, but had been shared and used in multiple studies of other conditions as 
well. In such instances, simply ‘remembering’ the special background and conditions in which the samples were 
collected is imperative. Similar entitlement debates are not uncommon in relation to biobanks, and the samples 
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contained within them,23 but universities appear to lack a common framework for working through many of the 
ethical, social and legal issues associated with long-term storage of tissue samples. 
 
In the present paper we aim to address some of these shortcomings by offering some recommendations on the 
sustainability of university-based biobanks.  
2. Methods and Materials 
This paper is based on insights from the interdisciplinary research project Global Genes, Local Concerns (GGLC) 
(http://globalgenes.ku.dk). The project ran from 2013 to the end of 2016 and was funded by the University of 
Copenhagen. GGLC sought to combine legal, ethical, social and scientific perspectives on cross-national 
biobanking and translational exploitation. Working in several work packages, the natural sciences group (genetics 
and biology) sought first to identify candidate genes in patients with chromosomal translocations and/or rare 
diseases, such as microcephaly and congenital heart disease in several countries (Denmark, Finland, Pakistan, the 
USA). The candidate genes were then subjected to functional analysis in tissue cultures or model organisms to 
study their role in specific cellular processes and/or the development of relevant organs such as the heart and brain. 
The legal, ethical and social components of the project sought to monitor this research process to better understand 
what ethical, legal and social challenges and questions arose about the collection of samples from international 
partners and their subsequent analysis in Denmark. Concentrating on biobanking in a university setting, the project 
aimed to study, and ultimately provide guidelines to overcome regulatory barriers to, biobank research and the 
utilization of research results, while at the same time securing the ethical legitimacy of the research and 
safeguarding societal interests in access to information and innovation. 
  
This paper is a synthesis of the overall findings on university-based biobanks and presents some of the 
shortcomings that we have observed during the course of the research project. We base our findings on the 
6 
following data: qualitative, semi-structured interviews with geneticists and biologists in Denmark, Pakistan and 
Finland; fieldwork24 in several countries, including Denmark, Pakistan and Finland; interviews with patients in 
Pakistan25 and Denmark;26 and policy documents, as well as legal text analyses in Denmark. Research was also 
conducted on aspects of commercialization with publicly funded biobanks in Estonia, Austria, Finland, and 
Luxembourg.27 These studies included university-linked biobanks and technology transfer office employees as an 
object of study.  
 
In addition, we have held several workshops with project members to discuss issues related to the collection of 
human tissue samples and the challenges raised by the long-term sustainability of these collections within 
universities. One theme that often arose in discussions was that most universities lack systematic methods for 
tracking and evaluating the various collections that are maintained within their facilities. As a result, we have 
sought to develop some general guidelines that could help university administrators evaluate and develop more 
systematic methods in managing the tissue collections housed on their premises. 
  
Discussion: Biobanks and special obligations 
  
In the following sections we discuss the special challenges and opportunities for university-based biobanks, based 
on our data and results in the GGLC research project. We focus on two issues. First, biobanks may create special 
challenges for universities simply because they have been collected and are being managed by university staff and 
universities. Travelling under the ‘university flag’ no doubt opens doors to researchers which are closed to, for 
instance, researchers from industry. Universities should take action to make sure that biobanking practices do not 
undermine the high status of universities in society, but also to guarantee that values such as openness which are 
central to university research are respected in biobanking. Second, because biobanks often constitute an important 
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scientific infrastructure, they need to be managed in ways which maintain their integrity and make them usable to 
outsiders. As indicated above, university biobanks are often not intended as biobank collections from the outset, 
but rather arise from ongoing research within the university. Hence, there is reason to assume that the collections 
are to some extent – perhaps, often implicitly – subject to the values, procedures and interests that guide not only 
university research at a higher level, but also interactions between researchers at a lower level. 
Biobanks and university research  
Universities generally enjoy a high degree of public trust, and with the exception of a few (highly publicized) cases 
of academic misconduct, citizens generally believe them to be trustworthy sources of new knowledge, technologies 
and innovation for the benefit of the population. This is largely a consequence of the universities’ institutionalized 
observance of the basic principles of research integrity (such as honesty, accountability, responsibility, rigor, 
efficiency and objectivity). For example, Section 3 of the University of Copenhagen’s rules on good scientific 
practice demand that research is conducted in a reliable manner; that primary data are kept secure and, as far as 
possible, made publicly available; that research results are presented openly and honestly; that there is openness 
regarding possible conflicts of interest; and that everybody who takes part in the research is credited in a fair 
manner.28 A major factor in preserving the public’s trust is transparency about any research being conducted at 
the university – research largely undertaken by the individual researchers. To this end, universities place explicit 
demands on researchers to appropriately and adequately preserve their data, and to be willing to share them with 
other researchers so that results can be replicated. To take another example from the University of Copenhagen, 
its policy on research data states that “the individual researcher is responsible for choosing appropriate and 
adequate methods for collecting, storing and archiving research data. [...] As a general rule, it must be possible to 
recreate research findings”.29   
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Transparency, as a fundamental principle of research integrity, is also observable in the wider scientific community 
- in many cases, willingness to share data is a prerequisite for publishing results in leading scientific journals. Thus 
the author submission guidelines for Nature state that “An inherent principle of publication is that others should 
be able to replicate and build upon the authors’ published claims. A condition of publication in a Nature Research 
journal is that authors are required to make materials, data, code, and associated protocols promptly available to 
readers without undue qualifications” (http://www.nature.com/authors/policies/availability.html, accessed Dec 19 
2017).    
 
Few would deny that universities are the most important arena for basic research. Basic research aims to advance 
our fundamental knowledge of the world. It is a prerequisite of applied science and research – and thus of the 
development of new applications, technologies and therapies within and beyond the university setting. One 
example is the discovery in 1960 at University of Pennsylvania of a small chromosome, the Philadelphia (Ph1) 
chromosome, in chronic myeloid leukemia (CML), a lethal hematological cancer.30 The Ph1 chromosome was later 
found to be a specific translocation between chromosomes 9 and 2231 which forms a fusion gene that encodes a 
new phosphorylating protein that drives CML.32 Subsequent screening for chemical compounds that block the 
phosphorylating activity of the fusion protein identified a compound33 that has revolutionized the treatment of 
CML.34 It can be seen, then, that basic research is a fundamental necessity in our society, underpinning such things 
as infrastructure and the health and well-being of citizens. 
 
Basic research is largely driven by university researchers’ curiosity about their field, not by the economic 
incentives that often characterize research in, for example, private pharmaceutical companies. It is often contended 
that for basic research to flourish and thrive – and in turn produce developments and technologies for the good of 
society through applied research – university researchers need, and should be granted, the academic freedom to 
focus on their particular research field without unnecessary regulations and demands. This follows from the right 
to academic freedom protected inter alia in the UNESCO Recommendation Concerning the Status of Higher-
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Education Teaching Personnel, which, in principle 29, emphasizes the right to “carry out research work without 
any interference, or any suppression, in accordance with their professional responsibility and subject to nationally 
and internationally recognized professional principles of intellectual rigor, scientific inquiry and research ethics”. 
The value of academic freedom is often institutionalized in university rules. For example, the ‘Academic Freedom 
at the University of Copenhagen’ code states that academic freedom is crucial in that it “ensures that the University 
contributes to a free, prosperous society by creating, sharing and applying new knowledge in its own right. [...] 
[UCPH] protects freedom of speech and research and makes room for creative and professional development of 
all employees with respect for the entire university community and the University’s overall objectives”.35  
 
This is no less important in the case of biobanks: to achieve the scientific development we want from university 
biobanks with respect to basic research, researchers should be allowed the freedom to focus on the basic research 
and not be subject to extensive regulations. This notion is instantiated by certain policies already regulating 
research. One example is the Danish Act on Research Ethics Review of Health Research Projects, which, in §10, 
mandates research ethics committees to give exemption in cases of registry-based research allowing researchers 
using register data to disregard the requirement of re-contact and informed consent provided that the research 
project does not pose health risks or other potential harms to donor(s). 
 
As the above shows, transparency and the sharing of data and material are paramount in university research. Hence, 
guidelines and principles are in place to promote them. However, it seems that the practice of data sharing between 
institutions and researchers is guided not only by articulated principles, but also by unspoken and/or implicit values 
and rules in particular scientific communities. In our data, researchers reported that they share data not primarily 
because they are required to do so by a university code and wish to fulfil their responsibilities as university 
researchers, but also for reasons including: potential co-authorship; wanting to sustain your own reputation as 
someone who is willing to cooperate or “is a nice person”; potential future benefits such as being invited to 
conferences based on one’s data; and/or being guided by the fact that one knows and likes the person asking for 
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data or material, and wants to do them a favor. As such, data sharing is influenced significantly by the interpersonal 
relations and personal preferences of individual researchers, who appear to be guided by values such as trust, 
recognition and reputation. This indicates that a significant portion of research conduct lies outside the scope and 
reach of university guidelines and regulations. This has obvious impact on the practice of data sharing, which is 
of major significance in the field of university biobanking.  
Biobanks as an important research infrastructure 
As we suggested earlier, university-based biobanks are a special kind of biobank for a number of reasons. In 
relation to their long-term storage, it is necessary to determine whether they are worth keeping for periods of time 
extending beyond their original or intended use. Criteria that universities and research groups should consider in 
making such determinations need to be found. We suggest that a number of scientific criteria need to be considered. 
Scientifically these can be grouped into the three general categories of quality, quantity and uniqueness. 
  
Freedman et al. (2015)36 have suggested that a major challenge facing biomedical research using tissue samples is 
the lack of reproducibility of research results.37 There are numerous reasons for this problem, but the major cause 
is variable sample quality. In university-based biobanks this can be a serious problem, since in sample collections 
which have been amassed over careers spanning many decades the standards and norms associated with sample 
collection and storage will often have changed numerous times. In addition to these changes, university-based 
biobanks may adhere to more than one set of standards which are used in other fields of practice, such as in the 
clinic or by the pharmaceutical industry. Since university biobanks conduct basic research for the most part, their 
standards for collection and storage standards may also differ from those in commercial and clinical settings. This 
problem can become compounded over the decades. We argue that, as institutions of scientific knowledge 
production, universities have an interest in supporting the development of quality standards to be adhered by their 
employees, as well as in relation to the collections they maintain. In determining which tissue collections or 
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biobanks are worthy of conservation or protection, it is therefore crucial to determine whether the samples can 
provide meaningful, as well as reproducible, information with scientific significance. 
 
Another challenge to long-term use of tissue collections relates to the secondary use of samples collected many 
years ago. During the past few decades, informed consent practices have changed considerably. Researchers may 
see new value or research possibilities in collections which were originally collected with a particular research 
goal in mind. Within biobanking there are many cases pointing up the ethical and legal challenges associated with 
secondary use of important collections.38, 39 Most universities lack policies for managing collections over long 
periods of time. 
  
Many university-based tissue collection practices will end up being used in commercial ventures. There are many 
examples of “special” biobanks/repositories/collections for cell lines (ATCC) and plasmids (e.g. Addgene, RIKEN 
in Japan etc.), as well as model organisms, which successfully collect, maintain and distribute biological samples 
to research communities across the world. Many of these collections started on a small scale in a university 
research lab and are now either funded by external grants or run like a private company (e.g. Addgene). Although 
samples from humans are subjected to much stricter rules and regulations, universities are often unaware of the 
activities which may be going on within their walls.  
  
We suggest that universities and university departments should, therefore, implement policies and practices which 
encourage the adoption of international standards and norms for collection and storage. This can be done by joining 
existing biobank networks which set standards and norms for biobanking: examples are TuBaFrost 
(http://www.tubafrost.org) for clinical pathology departments and biobankers and BBMRI-ERIC40 for national 
biobanking infrastructures. Encouraging implementation of existing and commonly shared standards and norms 
would also make existing collections of more interest to external collaborators, such as private industry, and make 
public-private collaboration more realistic. 
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A number of other initiatives are underway within academia to support the reusability of existing data. The FAIR 
(Findable, Accessible, Interoperable, Reusable) Principles, for example, seek to make searches for existing 
resources easier by using machines,41 and a number of other standards, such as the Big Data 2 Knowledge (BD2K) 
initiative and the Joint Declaration of Data Citation Principles (JDDCP), seek to strengthen the emphasis on data 
as a reusable resource.  In a similar vein, universities should become do more to encourage researchers to make 
their resources visible to the broader research community. 
 
A more university-wide approach to sample quality is also important in relation to the reliability and quality of 
scientific research that the universities conduct, and it plays a major role in the reputation, as well as publication 
standards, that universities meet. Currently university researchers and research groups maintain their own sample 
collections in a wide variety of storage facilities which may exhibit a range of practices relating to the way the 
samples were procured and are now maintained. Universities may want to investigate whether it is a better idea to 
offer researchers and research groups centralized biobanking facilities to support their work. 
  
The second important issue when evaluating whether university-based sample collections ought to be maintained 
beyond their original scope relates to biobank size. Biobank size does not necessarily refer to absolute numbers; it 
may be a matter of relative numbers. Some collections contain tens of thousands of samples from the general 
population, as is the case in cohort samples. Others include only dozens of samples, but they may nonetheless be 
important if the samples are from patients with very rare diseases. In this sense, a sample collection, though small 
in numbers, may represent all the collected samples that exist in the world and thus be a large collection in relative 
terms. Universities may wish to initiate discussions with their researchers in which questions about which 
collections are likely to be of great scientific value going beyond the original research collection purpose are 
tackled. 
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The third group of collections which may be of broader interest are unique collections. These are generally 
collections with materials or samples that are not held anywhere else in the world. Alternatively, they may be 
collections that have been set up in such a way that permits the study of questions or phenomena in a way that is 
impossible with other collections. The notion of a unique collection can also be extended to collections that can 
be used in conjunction with other high-quality data sets, healthcare records, or registries. The Nordic countries, in 
particular, have unique collections in that the samples they contain can be compared with other sources of data 
using social security numbers. These numbers are unique personal identifiers which can be used to collect other 
health-related data on individuals. Collections that are unique in this way make up a broader network of data 
resources which many countries, particularly the Nordic countries, have sought, over the years to maintain and 
develop. 
  
Universities can help to facilitate the professional collection and management of samples to ensure that the 
necessary quality standards are being met. Providing support for these activities will also help managers to 
determine which collections merit support for long-term sustainability and maintenance. The development of a 
common framework for maintaining collections which makes it unnecessary to apply for funding separately from 
numerous different sources could also help to support research groups. 
  
                     
Long-term Sustainability of Biobanks 
Based on the foregoing analyses we suggest that the long-term sustainability of university run biobanks requires 
universities to accept and shoulder the responsibilities arising from their status as universities and to recognize that 
collectively biobanks are an important research infrastructure with an importance that often goes beyond the 
university where the collection has begun its life.  
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It is very difficult to find ways to balance one's own short-term interests with broader and external interests. It is 
especially difficult if doing so imposes costs or requires one to identify values which are external - and therefore 
often unknown - to the immediate and recognizable interests of one’s own institution. The problems here are 
familiar from ‘homeless cohorts’, for example. A recent example in Denmark was a rare collection of nearly 10 000 
brains collected between 1945 and 1982 which had been stored in the basement of Aarhus Psychiatric Hospital. A 
move to a newly built hospital triggered discussion of the continuing need to maintain the collection. The 
University of Aarhus, which held administrative responsibility of the collection on behalf of the Region (the 
regional authority responsible for the delivery of healthcare), found that the scientific value of the collection did 
not justify the cost. The collection had been forgotten for many years, and only one researcher had used the samples 
in recent times. The scientific value was contested as letters of support were sent from all over the world and 
commentators criticized the decision to destroy the collection as a short-sighted savings exercise rather than a 
scientifically founded decision; it was said that the limited previous research interest was due to the fact that the 
university had made no investments in maintaining the collection.42 A period was fixed to determine whether 
anyone was willing to take over the collection. Otherwise it would be destroyed (it has not been reported as yet 
whether attempts to find an adoptive researcher were successful). The Danish brain collection is just one example. 
Every day around the world collections are simply forgotten in basements and cryotanks because there is no 
institutional framework recording what samples exist as researchers retire, die or move to other employers. 
Consequently, in many cases there is no framework within which to determine which samples should be kept and 
maintained. Records of existing collections of samples and assessments of their continuing scientific value are 
prerequisites if other researchers are to be granted access to samples. Whether or not open access to samples can 
be considered a duty is considered below. 
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Open access to samples?  
Samples collected by university-employed researchers or within university-hosted projects will often be directly 
or indirectly financed by the taxpayer. University-operated biobanks may as a result be subject to the same 
demands of open access that has characterized research in recent decades. One argument for this relates to the 
democratization of knowledge, and the idea that open access to research archives and journals helps change the 
public presence of science and scholarship and increase the circulation of this particular form of knowledge for 
the benefit of society (which financed the research in the first place). Another argument refers to the fact that there 
is an increased emphasis on political accountability and a corresponding call for “evidence-based policymaking” 
in government.43 The argument is that public funding is increasingly framed as an investment that will provide 
evidence-based applied uses for the common good of society and as such should be openly accessible. It follows 
from this line of argumentation that biobanks that were funded by the public and consist of samples donated by 
citizens can become such an infrastructure. Consequently, universities should consider to what extent open access 
to samples and data should be considered a duty – either of a scientific, or ethical or legal sort. This section aims 
to provide a framework within which universities can attend to issues of open access when local biobanks collected 
by researchers take on an institutional infrastructure. 
  
Biological samples in biobanks allow researchers from a variety of scientific backgrounds to ask questions about, 
for example, biological function and the relations between particular gene mutations and certain diseases. 
However, the ways in which the samples have been stored can influence not only what scientific answers 
researchers will obtain, but also the reproducibility of research results. Clearly, ensuring a certain level of quality 
of the samples is essential. Wilkinson et al. (2016)44 define four principles of data sharing which have also been 
endorsed under the ERIC regime: data should be findable, accessible, interoperable and reusable (these are the 
FAIR principles mentioned earlier). Storage of samples then becomes vital in meeting the FAIR principles, in 
terms both of quality assurance and of the criteria by which the samples are searchable/accessible. There are no 
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specific internationally agreed standards of quality on the preparation, storage and shipping of samples. However, 
inspiration for best practice can be drawn from repositories such as those mentioned above. 
  
Universities should also consider if any access criteria should be applied to samples and data held in biobanks. 
The World Medical Association’s Declaration of Helsinki, which outlines ethical principles that are applicable to 
research on identifiable human material and data, could serve as the basis for insisting that universities ascertain 
that the commissioning research project lives up to the following criteria: conforms to generally accepted scientific 
principles; is based on a thorough knowledge of the scientific literature or other relevant sources of information; 
and has adequate laboratory facilities. One solution here is for universities to set up Access Committees tasked 
with making scientific evaluations and decisions on criteria of access and access requests (as the UK Biobank has 
done). 
      
As detailed above, access to samples and data collected by a researcher or a research project is in practice governed 
primarily by trust, personal relations, the fear of being scooped by others in the race to publish first, and a desire 
for status in the relevant scientific field. When universities become custodians of biobanks, ways to address these 
informal mechanisms of access could include consideration of whether any quid pro quo requirements of access 
would be appropriate, such as co-authorship or acknowledgement of the sample provider in the published article. 
  
In assessing access to samples and/or data, universities must respect the rights and integrity of donors. A number 
of legal obligations flow from the protection of donors’ integrity. First, in allowing access to samples and data, the 
biobank manager must assess whether informed consent from the donor is needed and whether permission from a 
Research Ethics Committee is needed. In this regard, the country of origin of samples will matter, since different 
origin countries will impose different legal demands, and samples originating from abroad will often require re-
contact with the original sample provider to ascertain if access requests from new research projects can be granted. 
Second, a number of duties relating to data protection must be checked. The recipient must have security protocols 
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in place for the storage of samples or data and the recipient must not publish any material which could lead to the 
identification of individual donors. 
 
Compliance with these obligations will become increasingly important and complex following the arrival of the 
General Data Protection Regulation (GDPR) (Regulation (EU) 2016/679), which will be binding in its entirety 
and directly applicable in all Member States from May 25, 2018. 
 
The General Data Protection Regulation requires processing of personal data to be performed in accordance with 
principles of “lawfulness”, “fairness” and “transparency”. Under the new EU legislation, consent for data 
processing is not only the requirement; data must also be processed as per the standards set out in the regulation if 
it is to be lawful. Data subjects also have enhanced rights, including ‘data rectification’ (Art.16), which is the right 
to rectify any inaccuracy in relation to their personal data. Another important right offered to data subjects is the 
‘right to be forgotten’ or a ‘right of erasure’. This applies in cases where personal data are no longer necessary for 
the purposes of the research, or where they were not processed lawfully, or where the data subject withdraws 
consent (Art. 17). Researchers handling human data are thus bound by any request from a data subject to remove 
personal data collected by them. This duty does not arise, however, in certain cases, such as cases in which 
information is processed in public interest. Also, where data have been archived to be processed for scientific 
purposes in the public interest, the right of erasure may not be offered if it is “likely to impair the achievement of 
the objectives’ of that processing” (Art. 89). This essentially means that institutional responsibility is enhanced 
considerably, and that the duties of universities and data controllers working within them are greater. Those 
managing university-linked biobanks need to consider consent requirements carefully and ensure that biobanks 
respect data minimization and overuse of consent. The new requirements set forth by GDPR, and their applicability 
to biobanks, will need to be carefully studied, and every university biobank should have proper compliance 
guidelines in place.45     
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Apart from personal data, it is essential to consider practices involving allied research data. Contemporary research 
in molecular biology involves a high level of interoperability of wet biology with computer technology. This has 
resulted in a “data mirage”, meaning that it has become difficult to separate material (wet) data from other (dry) 
data secured through technical means. Against this background, university biobanks must evolve clearer practices 
for ownership and control of biological resources along with the data derived from such materials. 
 
 
Property rights 
  
Publicly funded biobanks are increasingly being treated as economic assets. They can be used to secure financial 
gains from research via tech-transfer and the protection of research results through patents and other Intellectual 
Property rights (IPR), such as copyright, trade secrets and database protection. Universities utilizing biobanks in 
this way must show due regard for the research value of samples and data, as they are custodians of the biobank’s 
resources. EU Recommendation CM/Rec (2016) 6 lays down the principles of governance for obtaining, storage 
and use of biological materials along with interoperability of data for research purposes. 
 
In Europe, the responsibilities of universities have been given certain navigational paths under EU Horizon 2020, 
which has established a set of rules concerning the exploitation and dissemination of project results, including 
their protection through IPR. Universities and other public research organizations are required, as beneficiaries, to 
take measures to implement the principles set out under the Code of Practice annexed to Commission 
Recommendation C (2008) 1329 of 10.4.200846 on the management of intellectual property in knowledge transfer 
activities. Under this Code, universities, while incentivizing innovation among their staff and students, are also 
required to seek protection of intellectual property, in line with the strategy and mission of the public research 
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organization, with a view to maximizing socio-economic benefits such as the concept of open innovation. The 
Code also recognizes institutional ownership – as opposed to "professor's privilege" – as the default legal regime, 
although ownership arrangements may vary in case of collaborative research where the rights are allocated to the 
different parties on the basis of a contractual agreement concluded in advance. Hence university-linked biobanks, 
while promoting the use of research resources, must seek to clarify the allocation of ownership of foreground 
intellectual property generated within the framework of the biobank-based project. In addition, many European 
countries have adopted legislation which requires universities to pursue ownership of inventions made by their 
employees via the patent acts. 
 
As a consequence of these initiatives, patent protection is often integral to research projects, including those that 
rely on biobanks. For this reason, it is vital to define the limits of patentable inventions. According to current 
European patent rules, and most importantly EC Directive 98/44/EC (Biotech Directive), inventions which satisfy 
the basic patentability criteria – i.e. novelty, inventive step and industrial applicability – shall be considered 
patentable even if they involve a product consisting of, or containing, biological material that previously existed 
in the natural world (Art. 3). Art. 5 makes it clear that this principle extends to human biological material provided 
that it has been isolated from the human body or otherwise produced by means of a technical process and (in 
relevant cases) that an industrial application of a sequence or a partial sequence of a gene has been disclosed in 
the patent application. Consequently, as soon as data derived from samples in a biobank can be used, for example, 
to link a certain genetic disorder to a disease, patent protection for the isolated genetic sequences or methods to 
generate modified human biological material becomes an option for researchers who can demonstrate that they 
have made an essential contribution to the invention. Defining the limits here is obviously extremely complicated 
and not something we shall pursue in the present discussion. In countries with legislation obliging universities to 
patent inventions, university researchers need to contact university patent experts if they so much as suspect that 
patent law could be applicable to their work. The university may decide to patent the invention and have the patent 
right transferred to them despite the interests of the inventor. Since the researcher’s duty to act arises when patent 
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protection is a possibility, the reach of patent law into university-based research goes beyond the limits of the 
legislation. It also follows from the special rules on university-based patents that universities themselves have an 
interest – and often indeed a legal duty – to secure patent protection whenever possible. In this way, the legal 
system has not only stacked the deck in favor of patent protection, but also generated a special interest for one of 
the stakeholders – universities – which may create tensions vis-à-vis other stakeholders (including employees). 
 
Apart from patent law, other types of entitlement schemes may be relevant, including trade secrets, copyright and 
database rights. The last of these, underpinned by the EU’s special rules on the protection of “databases” (Directive 
96/9), may come into play and will often provide exclusivity for databases containing genomic information. But 
these systems of ownership of data/information may create tensions between stakeholders by identifying different 
groups as the beneficiaries of an ownership right. Database rights, for instance, may point towards either the 
university, the funder, or the researcher, as the beneficial owner. Normally, the various stakeholders will use 
agreements to parcel such rights in ways they consider valid. 
 
The exploitation of publicly-funded research depends on proper management of intellectual property (in the 
broadest sense, encompassing inter alia inventions, software, databases and patents), and on the development of 
an entrepreneurial culture and associated skills within public research organizations which enhance interaction 
between the public and private sectors (rec C (2008) 1329). Where inventions arising out of biobank research are 
concerned, universities will often need to have special procedures in place to ensure both that potentially patentable 
inventions are reported and that genuinely patentable inventions are patented. Apart from patents, which always 
require target actions (applications) if they are to be obtained, various property rights may arise during the 
operation of biobanks. The administration of such rights requires special attention, strategy and tools, including 
special software solutions. The use of exclusive rights (such as database rights) must also be coordinated between 
the different actors. Otherwise the rights may prevent some actors from accessing and using the relevant database. 
Universities therefore need to have a system of coordination in place. 
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Importantly, the strategy is not predefined by the existence of property rights. Even where the most exclusive right, 
i.e. a patent, is involved, universities may still pursue a strategy based on Openness.47 The default rule and ambition 
for publicly funded and tax-exempt universities that engage in the patenting of crucial technologies should perhaps 
be that patents are used as much as possible to deliver the greatest public benefit and/or to support researchers in 
bringing their work to fruition (assuming they should engage in patenting at all in the first place). For example, if 
key technologies are being developed from university biobank-driven research projects involving various 
institutions, and if there are compelling reasons to engage in patent protection, university guidelines should 
encourage and incentivize patent applications making broad reference to the researchers involved and the 
institutions as co-inventors. Any resulting patents could then be cross-licensed to other research institutions either 
freely or on very favorable conditions.48 Such guidelines could also stipulate that patents should be used to fund 
academic consortia dedicated to studying the relevant technologies, or they could be applied to ignite robust and 
beneficial competition for commercial applications of the technology by licensing the patents on non-exclusive 
terms to a variety of industry competitors, with the licensing fees then being invested into further academic 
research.49 As exemplified by current developments in gene editing technologies, such licensing regimes could 
also be used as interim tools to address currently unsolved ethical dilemmas posed by emerging technologies that 
are not being sufficiently regulated by existing regulations and state law.50 In that way, patents could be used as 
technology transfer and innovation policy tools rather than swords and shields. 
 
Finally, it is important to bear in mind that (intellectual) property rights are just one of several issues that need to 
be addressed in the effort to enhance open science and data and sample sharing within the framework of public 
university biobanks. After all, it is not uncommon for university researchers to be happily unconcerned about, or 
simply ignore, IP rights. As we have detailed above, the competence and reliability of research partners, the trust 
that those partners are able to properly handle, utilize and further develop high quality data, the quality of the data 
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they expect to receive in return, and the trust that recognition and acknowledgments are properly respected – these 
are often the most decisive factors when researchers decide to share (or not to do so). Considering the amount of 
human intervention, work, skills, dedication and investment that is often required to generate and store high quality 
biobank data, it comes as no surprise to learn that scientists are often reluctant to share their data. They become 
what <AUTHOR>  calls “data huggers”51 and might be understandably inclined to protect their data through 
IPRs.52 
 
Such data need to be differentiated from machine-generated data, and public universities will have to find a way 
to address data-hugging. IP guidelines alone will not suffice to manage it. A sustainable solution will require 
additional strategies, such as the development of recognized data quality standards in collaborative research 
projects, guidelines on acknowledgements and co-authorship, and enforceable guidelines on research ethics. If 
these issues are not addressed, the vision and aspiration of openness and smart data sharing might be crushed by 
harsh realities, secrecy-driven competition, and even aggressively enforced IP rights. If the goal is an academic 
environment where IP rights are used as shelters and ploughs, rather than swords, and if we want to encourage the 
notion that university research and biobanks collaborate and compete on their capacity to generate and analyze 
data, rather than on their ability to protect and own high-quality data, all the above issues will have to be addressed 
collectively.  
 
Conclusion: A framework for sustainability  
In this paper we have sought to identify an important challenge facing universities in relation to the maintenance 
and curation of a scientific resource which has in our view been neglected. Traditionally, universities have sought 
to develop practices which accumulate and improve the research resources they maintain, such as library 
collections and other types of archived research data. Biobank samples, however, have not received the level of 
attention and interest that other resources have garnered within universities. 
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We suggest that universities should develop procedures which ensure that collections of human biological material 
stored within their facilities are sustainable when those collections are deemed to have special long-term value. 
The procedures should include the possibility of reassigning custodianship of the collections when their original 
custodian retires or moves to work elsewhere. They should also ensure the proper destruction of collections and 
data that are no longer needed. 
  
We also suggest that universities develop both a short-term and a long-term perspective on the collection and 
storage of human tissue collections. Universities should recognize that the value of some biobanks transcends the 
interests of the university itself and the individual researcher and research group. Some collections may be of great 
value to the broader scientific community. It is important, however, that the rights and interests of the original 
custodian are also respected when the long-term sustainability of important collections is discussed. 
 
It is essential for public institutions like universities to recognize that the effective use of tools such as intellectual 
property rights and knowledge transfer mechanisms must enable socio-economic research to proceed within a 
commitment to responsible research.53 Biomedical research, in particular, is contingent on the swift translation of 
research results to the benefit of patients. In this respect, university-linked biobanks must effectively engage in 
public-private partnership research which effectively enables such commitments to responsible medical research.  
  
In concrete terms, we suggest that universities should be obliged to have institutional arrangements in place that 
enable them to identify special cases and decide whether unique collections should be preserved or destroyed. 
What these arrangements end up involving will depend on the individual universities themselves, and we would 
urge them to enter into dialogue with their research staff, as well as other relevant stakeholders (e.g. funding 
agencies and patients), to develop guidelines that the researchers are ready to commit to. Given that the majority 
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of tissue collections housed in universities have been collected with public funding, we see this process as a matter 
of respecting the efficient use of public resources.   
  
 
[TABLE 1: RECOMMENDATIONS ON SUSTAINABLE MANAGEMENT OF UNIVERSITY 
BIOBANKS] 
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